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Background: Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative motor neuron disease that
involves activation of the immune system and inflammatory response in the nervous system. Reduced level of
the immuno-modulatory and anti-inflammatory protein alpha-1-antitrypsin (AAT) is associated with
inflammation-related pathologies. The objective of the present is to determine AAT levels and IL-23 in the
cerebrospinal fluid (CSF) of ALS patients and control group.
Findings: CSF samples from newly diagnosed ALS patients and age-matched controls were analyzed for AAT and
IL-23 by ELISA and magnetic luminex screening, respectively. A statistically significant reduction of 45 % in mean
AAT levels was observed in the CSF of ALS patients (21.4 μg/ml) as compared to the control group (mean 38.8 μg/ml,
p = 0.013). A statistically significant increase of 30.8 % in CSF mean levels of the pro-inflammatory cytokine IL-23 was
observed in ALS patients (1647 pg/ml) in comparison to the controls (1259 pg/ml, p = 0.012). A negative correlation
coefficient (r = −0.543) was obtained by linear regression analysis of the two measured parameters (p = 0.036).
Conclusions: Reduced AAT and elevated IL-23 CSF levels support the notion of neuroinflammatory process occurring
in ALS patients. Increasing AAT levels in the patients’ nervous system should be further investigated as a new
therapeutic approach and a novel potential tool for ALS treatment.
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Background
Amyotrophic lateral sclerosis (ALS) is an incurable, neu-
rodegenerative motor neuron disease with devastating
impact that relentlessly causes injury and death of the
lower motor neurons in the brainstem and spinal cord
and of the upper motor neurons in the motor cortex [1].
Patients experience signs and symptoms of progressive
muscle atrophy and weakness, fatigue and dysphagia,
and typically succumb to respiratory failure [2, 3]. The* Correspondence: wormser@cc.huji.ac.il
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fatal outcome ranges from 20 to 48 months. However, a
relatively small group (10–20 %) of the patients survives
more than 10 years [4]. ALS is most commonly a spor-
adic disease while 10–15 % of cases are familial [5]. The
worldwide incidence of ALS is approximately 2–3 per
100,000 individuals [1], except for a few high-incidence
foci, such as the Kii Peninsula and Guam [6].
Accumulating data support the notion that inflamma-
tory processes are involved in ALS pathophysiology. Acti-
vation of microglia and astrocytes was demonstrated in
both animal model and humans. Brain infiltration of both
CD4+ and CD8+ T lymphocytes was shown in ALS pa-
tients [7]. Regulatory T lymphocytes number was found to
be a prognostic factor both in animal models of ALS and
in human patients affected by the disease [8]. Alterationsle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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such as IL-6, IL-10, GM-CSF, G-CSF, IL-2, IL-4, IL-8, IL12,
IL-15, IL-17, IL-18, basic FGF, VEGF, and IFN-gamma were
observed in CSF of ALS patients [9–12].
Apart from cytokines and growth factors, proteinase
inhibitors play a central role in controlling inflammation.
For instance, the serine proteinase inhibitor (serpin)
alpha-1-antitrypsin (AAT) blocks neutrophil elastase and
prevents pathological tissue disruption. Thus, its absence
may lead to certain lung pathologies such as pulmonary
emphysema, cystic fibrosis, and chronic obstructive lung
disease [13]. In addition, the immuno-modulatory activ-
ities of AAT is expressed by controlling proinflammatory
cytokine release [14], binding to complement C3 [15] and
neutrophil functions [16]. Due to its anti-inflammatory
properties, AAT is a drug candidate for various disorders
including panniculitis, diabetes mellitus, rheumatoid arth-
ritis, vasculitis, and fibromyalgia [13]. In view of the key
function of AAT in controlling immunological response
and inflammation, this study was aimed to quantitatively
determine the levels of this protein and for comparing the
pro-inflammatory cytokine IL-23, in CSF specimens of
ALS patients and control group.
Subjects and methods
Study participants
ALS patients were recruited from a case series of residents
of the Emilia-Romagna region, northern Italy. They were
diagnosed with definite or probable ALS (revised El Escor-
ial criteria) at the ALS Center of the Modena University
Neurological Department from 2001 to 2011, and under-
went lumbar puncture due to diagnostic procedures. This
group included 58 consecutive patients with sporadic
ALS; only 15 of them had at least 1 ml CSF available for
the present study. The 15 patients (10 males, 5 females)
had at onset a mean age of 52 years (range 31–62 years);
13 patients presented with spinal onset and 2 with bulbar
onset ALS. No patient presented with ALS-associated
dementia or extrapyramidal signs. Distributions of pheno-
types were as follows: 8 classic, 3 flail, 2 bulbar, and 2
upper motor neuron predominant phenotype. Mean dis-
ease duration from onset to death or last observation was
67 months. All the patients started Riluzole treatment
after CSF sample withdrawal. Ten of them underwent
genetic screening including all the major genes that are
implicated in ALS (SOD1, C9ORF72, FUS, TDP43) with
none testing positive. Genetic analysis could not be per-
formed in the remaining patients due to lack of available
blood samples.
The control population consisted of residents in the
Emilia-Romagna region who were admitted to the same
department between 2001 and 2011, and underwent
lumbar puncture because of suspected but later on un-
confirmed neurological disease. The signs and symptomsthat led to neurological examination and lumbar punc-
ture were mainly headache and paresthesia. Fourteen of
these subjects were randomly selected and age matched
(±10 yrs) 1:1 to ALS patients. The 14 age-matched con-
trols had a mean age of 54 years (range 32–71 years). All
the control patients were subsequently discharged from
hospital without a diagnosis of a major disease.
Informed consent for diagnostic lumbar puncture (LP)
was obtained from all the patients, and utilization of the
CSF specimens for the present study was approved by
the Modena Ethical Committee.
Sample collection
Approx. 6–8 mL of CSF were collected by LP from each
patient and immediately stored at −80 °C until in poly-
propylene tubes. A 1 ml aliquot was transported by air
courier, deep frozen in dry ice to the Institute of Drug
Research (U. W.’s laboratory) at the Hebrew University
of Jerusalem, and kept continuously frozen until use.
Determination of AAT and IL-23
AAT was determined (monoplicate) by ELISA kit vali-
dated for CSF (Assaypro, St. Charles, MO, USA, Cat No.
EA5101-1) and cytokines by Human Magnetic Luminex
screening assay (R&D Systems, Minneapolis, MN, USA).
Data analysis
Statistical significance of the difference between the ALS
and control groups was calculated by Student’s t test.
Correlation coefficient of AAT and IL-23 data in ALS
patients was calculated by Pearson’s analysis.
Results and discussion
The present study demonstrates a statistically significant
reduction of 45 % in AAT mean CSF levels in ALS
patients (21.4 μg/ml) as compared to the control group
(mean 38.8 μg/ml, p = 0.014) (Fig. 1a, Table 1). The
median values showed even greater reduction of 53 % in
AAT levels in the patients (18 μg/ml) in comparison to
the controls (38 μg/ml) (Table 1). These values are com-
parable to those previously found in human CSF by other
laboratories [17–19]. In line with these findings, a statisti-
cally significant increase of 30.8 % in CSF mean levels of
the pro-inflammatory cytokine IL-23 was observed in ALS
patients (1647 pg/ml) in comparison to the controls
(1259 pg/ml, p = 0.012) (Fig. 1b, Table 1). The median
value showed 36 % increase in the patients group
(1678 pg/ml) as compared to the controls (1229 pg/ml)
(Table 1). No statistically significant differences between
both groups were detected for the other cytokines (IL-8,
MCP-1, IL-17A, growth-related oncogene-alpha, unpub-
lished data). As expected, a negative correlation coefficient
(r = −0.544) was obtained by linear regression analysis of
the two measured parameters in ALS patients (p = 0.036)
a b
c
Fig. 1 AAT and IL-23 levels in CSF of ALS patients and controls. CSF specimens of patients and controls were determined for AAT (a) and IL-23
(b) by ELISA kit and Human Magnetic Luminex screening assay, respectively. Results are expressed as mean ± SEM using Student’s t test for calculating
the statistical significance of the difference between the two tested groups. N = 15 for both AAT and IL-23 in ALS group while in the controls n = 14
for AAT and n = 13 for IL-23 determinations. *p = 0.014, **p = 0.012; c Linear regression (Pearson test) of AAT and IL-23 in ALS patients.
R = −0.544; p = 0.036
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and IL-23 in the control group (r = 0.065) (linear regression
data not shown).
To our best knowledge, this is the first report on a signifi-
cant reduction of AAT levels in CSF of ALS patients. The
lack of this anti-inflammatory and immune-modulatory
protein is inversely correlated with the increase of the pro-
inflammatory cytokine IL-23 in the patients. These findings
are compatible with the accumulating evidence for the link
between ALS and inflammation [7, 20] expressed by alter-
ations in levels of cytokines and growth factors [9, 10, 21].
Brettschneider and colleagues through proteomic ana-
lysis identified two proteins that were upregulated (alpha-
1-antitrypsin precursor and Zn-alpha-2-glycoprotein) and
three proteins (ceruloplasmin precursor, transferrin, and
beta-2-microglobulin) that were downregulated in theTable 1 Quantification of AAT and IL-23 in CSF of ALS patients and
Tested parameter Tested group Mean ± SEM
AAT Control 38.8 ± 6.0 μg/ml
AAT Patient 21.4 ± 3.1 μg/ml*
IL-23 Control 1259 pg/ml
IL-23 Patient 1647 pg/ml**
CSF specimens of patients and controls were determined for AAT and IL-23 by ELIS
Results are expressed as median or mean ± SEM using Student’s t test for calculatin
N = 15 for both AAT and IL-23 in ALS group while in the controls n = 14 for AAT and
*p = 0.014, **p = 0.012
aExpresses the percent of change (reduction or elevation) taking the control as 100CSF of ALS patients [22]. Elevation of AAT precursor and
reduction in AAT levels may stem from inappropriate
conversion of the precursor to its final product leading to
decrease in AAT levels in CSF of ALS patients. Another
study identified serine proteases and serpins (alpha-1-anti-
trypsin, alpha-1-anti-chymotrypsin, and protease nexin I)
in motoneurons in neurofilament conglomerates suggest-
ing that the imbalance of serine proteases and internalized
serpins may play a role in the pathogenesis of ALS [23].
Whether altered AAT levels are a result of the patho-
logical processes in the neuronal system or a factor in-
volved in the evolution of the disease remains an open
question. Nevertheless, the central role of AAT in con-
trolling various inflammatory processes, and the variety
of diseases associated with inappropriate levels of AAT
may lead to the notion that lack of this protein may becontrols
Changea (%) Median Changea (%)
38.0 μg/ml
−45 18.0 μg/ml −53
1229 pg/ml
+30.8 1678 pg/ml +36
A kit and Human Magnetic Luminex screening assay, respectively.
g the statistical significance of the difference between the two tested groups.
n = 13 for IL-23 determinations
%
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course. Should these results be confirmed in larger stud-
ies, increasing levels of this protein in the neuronal system
of the patients may serve as a novel therapeutic approach
for ALS. Replacement therapy by intravenous augmenta-
tion of AAT has been approved by the US-FDA for AAT
deficiency such as in individuals with severe COPD or
emphysema [24]. However, targeting the CNS is more
convoluted and challenging and needs an alternative route
of administration. As it is evident now that a direct path-
way connects a submucosal compartment in the nasal
passages to brain interstitial fluid, the nose-to-brain deliv-
ery of large molecular weight molecules can be feasible via
intranasal administration. Thus, the central nervous sys-
tem accessibility can be achieved by intranasal administra-
tion of a nanotechnology-based compounded protein [25],
which may also be a convenient and efficient procedure
for ALS patients.
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